Previously it was established that infusion of glial cell line-derived neurotrophic factor (GDNF) protein into grafts of embryonic dopamine cells has a neurotrophic effect on the grafted cells. In this study we used a nonviral technique to transfer the gene encoding for GDNF to striatal cells. Plasmid DNA encoding for GDNF was compacted into DNA nanoparticles (DNPs) by 10 kDa polyethylene glycol (PEG)-substituted lysine 30-mers (CK 30 PEG10k) and then injected into the denervated striatum of rats with unilateral 6-hydroxydopamine lesions. Sham controls were injected with saline. One week later, experimental animals received either a ventral mesencephalic (VM) tissue chunk graft or a cell suspension VM graft implanted into the denervated striatum. Grafts were allowed to integrate for 4-6 weeks and during this period we monitored spontaneous and drug-induced motor activity. Using stereological cell counting we observed a 16-fold increase in the number of surviving TH + cells within tissue chunk grafts placed into the striatum pretreated with pGDNF DNPs (14,923 ± 4,326) when compared to grafts placed into striatum pretreated with saline (955 ± 343). Similarly, we observed a sevenfold increase in the number of TH + cells within cell suspension grafts placed into the striatum treated with pGDNF DNPs when compared to cell suspension grafts placed into the saline dosed striatum. Behaviorally, we observed significant improvement in rotational scores and in spontaneous forepaw usage of the affected forelimb in grafted animals receiving prior treatment with compacted pGDNF DNPs when compared to grafted animals receiving saline control pretreatment. Data analysis for protein, morphological, and behavioral measures suggests that compacted pGDNF DNPs injected into the striatum can result in transfected cells overexpressing GDNF protein at levels that provide neurotrophic support for grafted embryonic dopamine neurons.
INTRODUCTION
grafted neurons, particularly following the influx of a large numbers of exogenous cells into a brain region that harbors a limited source of nutrients and growth factors. Experimental studies using fetal implants to improve motor function in animals with experimental Parkin-To overcome this obstacle, attempts have been made to supplement neural grafts with growth factors as a means son's disease have shown promise (2,4,8,53) while clinical trials using fetal implants have shown only limited to enhance the survival of the grafted dopamine neurons [for review see (9, 52) ]. In particular, glial cell line-derived therapeutic benefit to Parkinson's patients (15, 19, 22, 23, 26, 32, 35) . The limited success of neural transplants may neurotrophic factor (GDNF) has been used as a neurotrophic factor supplement to increase the survival of be attributed to the significant cell loss that occurs following transplantation into the brain. Experimental evi-grafted dopamine neurons. It has been shown that pretreatment of grafts with GDNF (3,44), direct infusion of dence suggests that a majority of grafted ventral mesencephalic cells succumb to necrotic or apoptotic cell death GDNF protein into the graft (36, 41, 49) , release of GDNF from cells encapsulated by polymers (1, 38) , or cografts soon after the grafting procedure and as early as the first 4 days after grafting (11, 31, 42, 43) . The adult brain may of cells secreting GDNF (48) increase of the survival and function of grafted dopamine neurons. More recently, not contain the appropriate amount of growth factors that are required for the maintenance and survival of viral vector technology has been used to overexpress 1184 YUREK AT AL.
GDNF at the graft site as a means to enrich the neuro-CpG-depleted luciferase gene was amplified from the plasmid pModLucSh (Invivogen) using 5′-ATACAC trophic environment for grafted cells (12, 16) . In the present study we used a nonviral gene therapy technique CATGGAGGATGCCAAGAATATTAAG and 5′-ATA CAACTAGTCTAGATTATTTGCCACCCTTCTTGG to compact plasmid DNA encoding for GDNF and then injected these nanoparticles into the denervated striatum CCT primers. The stop codon (TAA) and two restriction sites (XbaI and SpeI) were added to the 3′ end during in order to transfect striatal cells and overexpress GDNF prior to the grafting procedure.
amplification. The obtained PCR fragment was digested with NcoI and SpeI and subcloned into the pCpG-mcs/ Compacted DNA nanoparticles (DNPs) represent a promising nonviral technology that is safe and has been NcoI/NheI vector (Invivogen). Then hEF1-α promoter and synthetic intron were deleted using SpeI and NcoI. shown to be effective in the lung (54, 55) , nasal mucosa (19) , eye (13) , and brain (51) . Single molecules of plas-
The polyubiquitin C promoter, first exon and intron sequence were amplified from the pUbLux plasmid (17) mid DNA can be compacted by polycations to form colloidally stable nanoparticles that have the minimum pos-using 5′-ACATATCTAGACTGCAGGCCTCC-GCGC CGGGTTTTG and 5′-GTCTTCCATGGTGGCTAGCT sible theoretical size based on the partial specific volumes of the constituent components (24) . A preferred polyca-CGTCTAACA primers. Additional XbaI, PstI, and NcoI sites were added during amplification. The PCR frag-tion is polyethylene glycol substituted lysine 30-mer peptides, which facilitate cell entry and nondegradative ment was digested with XbaI and NcoI and subcloned into the prepared promoterless SpeI/NcoI vector de-trafficking to the nuclei of postmitotic cells by associating with cell surface nucleolin protein (10, 24, 54) ; other scribed above. The mCMV enhancer was deleted from the obtained vector using PstI. pGDNF (3,997 bp): The laboratories have shown that nanoparticles <25 nm in size use nondegradative pathways to reach the perinu-GDNF gene open reading frame was cut from pLenti-GDNF-IRES-GFP/BamHI (blunted with Klenow)/NheI clear region (20) . These particles are completely synthetic, can be designed to diminish an adverse immune (5, 6) and subcloned into pUL/XbaI (blunted with Klenow)/NheI vector. Figure 1 shows the plasmid map response, are stable in saline and nuclease-rich environments, and can be formulated as particles with minimum for pGDNF. diameters of 8-11 nm (14) . In postmitotic cells, strands
Preparation of Condensing Peptide of naked DNA that ultimately survive cell entry and the cytoplasmic environment must then pass through the nu-L-Cysteinyl-poly-L-lysine (UCB Bioproducts, Inc.) was conjugated with 10-kDa polyethylene glycol (PEG) clear membrane pore, which presents another obstacle given the extended size of hydrated DNA. Nanoparticle (Nektar Therapeutics) as described in Liu et al. (24) except that trifluoroacetate counterion was replaced with technology can circumvent these problems by: 1) protecting DNA from degradation, and 2) facilitating transit acetate by size-exclusion chromatography on Sephadex G-25 before lyophilization of the PEGylated peptide. of compacted DNA, if the nanoparticles are sufficiently small, across the 25-nm nuclear membrane pore of post-Formulation of Compacted DNA Nanoparticles mitotic cells (24) . When dosed in the lung, compacted DNA generates several hundred fold increased transgene Compacted DNA was manufactured by adding 20 ml of DNA solution (0.1 mg/ml in water) to 2.0 ml of activity compared to naked DNA in postmitotic lung epithelial cells (52). In the mouse retina, local delivery of PEGylated condensing peptide (3.2 mg/ml in water) at a rate of 4 ml/min by a syringe pump and through sterile compacted DNA transfects >90% of postmitotic photoreceptor cells (13) .
tubing ended with a blunt cannula. During this addition, the tube with peptide was vortexed at a controlled rate In this study we evaluated compacted DNPs following direct injection into the rat brain adjacent to the graft so that the two materials mixed instantaneously. Peptide and DNA were formulated at a final amine-to-phosphate site. The study was designed to determine whether this technique could be used to overexpress GDNF protein ratio of 2:1. The compacted DNA was then filtered through a vacuum-driven sterile filter with a 0.2-µm in the denervated striatum to levels that provided neurotrophic support for embryonic dopamine neurons grafted as tissue chunks or cell suspensions.
MATERIALS AND METHODS

Plasmid Construction
DNA vectors were constructed using standard molecular biology techniques, following by restriction analysis and sequencing of subcloned regions (37) . pKCPIRlucBGH (5,352 bp) is described in Ziady et al. (54) . pUL: The polyethersulfone membrane. The filtered compacted administer a left intrastriatal injection of 28.0 µg of compacted pGDNF DNPs (3.5 µg/µl) or saline at a rate DNA was then concentrated 20-30-fold using VIVASPIN centrifugal concentrators (MWCO 100k). The concen-of 0.5 µl/min in four sites (AP +0.5, ML +2.5, DV1 −6.5, DV2 −5.0; AP +0.5, ML +4.0, DV1 −6.5, DV2 trated DNA was then diluted 20-30-fold with sterile 0.9% NaCl for injection (Baxter) and concentrated again −5.0). Needle was left in place for 2 min following each injection and withdrawn from brain at a rate of 1 mm/ 20-30-fold to remove excess peptide and exchange water with physiologic saline. The final concentration of min. Prior studies indicate effective brain delivery of the nanoparticles with minimal backflow (51) . compacted DNA was 3.5 mg/ml. After formulation, the compacted DNA underwent several quality control tests, Tissue Dissection for ELISA Assays including sedimentation, turbidity, gel electrophoresis, transmission electron microscopy, and fluorescamine For striatal dissections, brains were removed from euthanized animals and then placed upside down (ventral assays, as described in Ziady et al. (54) and Liu et al. (24) . Also, endotoxin levels were checked using an surface facing upwards) into a stainless steel brain matrix (RMB-4000C, ASI Instruments). For the following ENDOSAFE PTS (Portable Test System) manufactured by Charles River Laboratories and were <5 EU/ descriptions, the approximate stereotaxic coordinates are listed in parentheses. The initial coronal cut was targeted mg of DNA. Estimated number of pGDNF nanoparticles are 8.0 × 10 11 particles/µl. at a level just caudal to the optic chiasm (ϳAP −0.5) and a second cut was made 3.0 mm anterior to the initial Animals cut. The 3.0-mm-thick coronal slab formed by these two cuts was removed from the brain matrix and then di-Male Sprague-Dawley rats were obtained from Harlan Farms and used in this study. Animals were housed vided into two pieces along the midline. Both the left and right striatum were dissected from the two pieces. in environmentally regulated rooms and had free access to food and water for the duration of the study. All ani-A rectangular piece of tissue was dissected by making the following cuts: 1) a cut parallel to the midline was mal procedures were conducted in strict compliance with approved institutional protocols, and in accordance made just lateral to the lateral ventricle, 2) a cut parallel to the midline was made just medial to the lateral aspect with the provisions for animal care and use described in the Guide for the Care and Use of Laboratory Animals of striatum at the striatum/corpus callosum border, 3) a cut perpendicular to the midline was made just ventral (28) .
to the dorsal aspect of the striatum at the striatum/corpus 6-Hydroxydopamine Lesion callosum border, and 4) a cut perpendicular to the midline was made just dorsal to the anterior commissure. To establish the Parkinson's disease model, all rats were given unilateral 6-hydroxydopamine (6-OHDA) le-Quantification of GDNF by Enzyme-Linked sions of the left nigrostriatal pathway; 6-OHDA (Sigma) Immunosorbent Assay (ELISA) was dissolved in 0.9% saline (containing 0.2% ascorbic acid) at a concentration of 3.0 µg/µl and stereotaxically Protein levels of GDNF were measured in tissue samples. Each tissue sample was weighed and immediately injected into the nigrostriatal pathway of anesthetized rats at a rate of 1.0 µl/min for 2 min. Each rat received frozen on dry ice. Subsequently, each tissue sample was homogenized in 300 µl volume of homogenate buffer two injections of 6-OHDA: one injection in the medial forebrain bundle (AP −4.4, ML 1.2, DV −7.5) area and [400 mM NaCl, 0.1% Triton X, 2.0 mM EDTA, 0.1 mM benzethonium chloride, 2.0 mM benzamidine, 0.1 mM the other in the rostral pars compacta of the substantia nigra (AP −5.3, ML 2.0, DV −7.5); all coordinates re-PMSF, aprotinin (9.7 TIU/ml), 0.5% BSA, 0.1 M phosphate buffer, pH 7.4]. The homogenate was centrifuged ported in this study represent millimeter adjustments from bregma (AP, ML) and below the dural surface for 10 min at 10,000 × g at 4°C. Tissue homogenates were assayed using a GDNF E max TM ImmunoAssay Sys-(DV) with the top of the skull in a flat position. This technique routinely produces complete lesions of dopa-tem (Promega; Madison, WI). mine neurons in the A9 and A10 midbrain regions, and Ventral Mesencephalic Tissue Chunk Grafts near complete denervation of dopaminergic fibers innervating the ipsilateral striatum.
One week after the compacted pGDNF nanoparticle injections, animals were anesthetized and placed in a Compacted pGDNF DNPs Injections stereotaxic apparatus. At the same time, the ventral mesencephalon was dissected from E14 fetuses obtained from Five weeks following 6-OHDA lesion, animals were divided into two groups: compacted pGDNF injection or timed pregnant Sprague-Dawley rats (Harlan Farms) and stored individually in a cold, sterile, calcium/magne-saline (sham). Animals were anesthetized and placed in a stereotaxic apparatus. A 30-gauge needle was used to sium-free buffer (CMF; 0.15 M NaCl, 8.0 mM Na 2 HPO 4 , 2.7 mM KCl, 1.5 mM KHPO 4 , 26.0 mM rats show equal usage of right and left forepaws during exploratory behavior. NaHCO 3 , 0.1% glucose, 100 mg/ml streptomycin, 2.5 mg/ml fungizone, pH 7.2). The ventral mesencephalon from a single fetus was drawn into the blunt end of a Amphetamine-Induced Rotational Behavior 22-gauge spinal needle and stereotaxically placed into Animals with 6-OHDA lesions were given a systemic the denervated striatum of the recipient animal at the injection of d-amphetamine (5 mg/kg) in saline and following coordinates: AP +0.5, ML +3.3, DV −5.8.
placed inside opaque 16-in.-diameter cylindrical chambers that were positioned directly beneath a video cam-Ventral Mesencephalic Tissue Cell Suspension Grafts era. The video camera was connected to a Videomex V One week after the compacted pGDNF nanoparticle image motion computer system (Columbus Instruments, injections, the ventral mesencephalon was dissected from Columbus, OH). The total number of 360°clockwise or E14 fetuses obtained from timed pregnant Spraguecounterclockwise rotations was measured during each Dawley rats (Harlan Farms) and stored in a cold, sterile, 90-min test session. Scores were taken at 4 and 5 weeks oxygenated calcium/magnesium-free buffer (CMF; 0.15 postlesion and 4 and 5 weeks postgraft. M NaCl, 8.0 mM Na 2 HPO 4 , 2.7 mM KCl, 1.5 mM KHPO 4 , 26.0 mM NaHCO 3 , 0.1% glucose, 100 mg/ml Immunohistochemistry streptomycin, 2.5 mg/ml fungizone, pH 7.2). Embryonic
All rats were anesthetized with Fatal-Plus TM (0.88 ml/ tissue was pooled and rinsed with CMF; a cell suspenkg, IP; Vortech Pharmaceuticals, Dearborn, MI) and sion was prepared using a 0.125% trypsin solution (Intranscardially perfused with cold 0.9% saline followed vitrogen, Carlsbad, CA) followed by inactivation with by 4% buffered paraformaldehyde (pH 7.4 in 0.1 M 1.0 ml newborn calf serum (Invitrogen) and 500 µl of phosphate buffer). Brains were postfixed overnight in DNase (0.5 mg/ml) in 3.5 ml Hank's balanced salt solu-4% paraformaldehyde and transferred to 30% sucrose. tion (HBSS) (Invitrogen). Cells were triturated with a Sections (40 µm) were cut using a sliding microtome 22-gauge needle 15 times, placed drop-wise on top of and placed into a cryoprotectant solution at −20°C (47). sterile fetal bovine serum (Invitrogen), and spun at 1000
For immunohistochemical detection of markers, freerpm for 10 min. Fetal bovine serum was aspirated and 1 floating sections were first rinsed in 0.1 M phosphate ml of HBSS was added to cell pellet and triturated to buffer (22 mM NaH 2 PO 4 and 80 mM K 2 HPO 4 , pH 7.2) create a single cell suspension. Cells were counted using followed by 3% H 2 O 2 treatment to inhibit endogenous the trypan blue exclusion technique and a suspension peroxidase activity. Sections were then rinsed in 0.1 M was made at a concentration of 200,000 cells/µl. Cells PO 4 and 0.1 M PO 4 -Triton followed by an overnight inwere drawn up in a 30-gauge needle and 2 µl of cell cubation in primary antisera containing a monoclonal suspension was injected into the denervated striatum at antibody against tyrosine hydroxylase (TH; 1:4000; a rate of 0.5 µl/min at the following coordinates: AP Chemicon). The sections were then incubated in an af-+0.5, ML +3.3, DV −5.8.
finity-purified biotinylated goat anti-mouse IgG secondary antibody (1:400, Chemicon) and then incubated in Spontaneous Motor Test (Cylinder Test) an avidin-biotin-peroxidase complex (Vector Labora-Spontaneous exploratory limb usage was analyzed tories). Staining was completed by placing sections in a using a modified forelimb asymmetry technique (39). 0.003% H 2 O 2 solution containing diaminobenzidine Rats were placed into a clear, Plexiglas cylinder (25 cm chromagen to visualize the reaction. tall, 16 cm ID) and spontaneous activity was videotaped for 5 min. Videotapes were played back in order to Stereology quantify the number of times the rat placed the left, right, or both forepaws on the wall of the chamber; the An Olympus BH-2 microscope was used to visualize tissue sections. We used Bioquant Life Science version experimenter was unaware of the treatment group. The total number of forepaw touches was counted for each 8.12.20 for stereological cell quantification using the optical fractionator method (40) . The graft was delineated animal during the 5-min session and the percent usage of the left or right forepaw was calculated by dividing at 4× and TH + cells were subsequently counted at 40× with a 100 × 100-µm 2 grid cell area and a 100 × 100 the counts for individual left or right forepaw touches by the total number of forepaw touches. Animals with µm 2 counting grid. We examined every third section (40 µm thick) through the entire rostral-caudal length of the severe 6-OHDA lesions typically use the ipsilateral forepaw 90% of the time (e.g., a rat with a lesion of the left graft. Optical dissector height was 30 µm with a guard volume set at 5 µm. Graft volume estimates were made nigrostriatal pathway will use the left forepaw 90% of time during exploratory behavior). On the average, naive using the Cavalieri method (27) .
Statistical Analyses tal pathway. Pregraft scores, shown in Figure 3 , indicate that animals in each treatment group had similar lesions. The α level of significance was set at p < 0.05. Anal-Rotational scores were tested again 4-5 weeks postgraft. ysis of variance (ANOVA) or t-tests were used for sta- Figure 3 shows grafts in all treatment groups successtistical analyses; choice of test was dependent on the fully attenuated rotational behavior. Statistical analysis experimental design. For rotational behavior and cylinof rotational scores revealed a significant Treatment × der test scores, data were analyzed using repeated mea-Time interaction for the chunk graft treatments [F(1, 6) = sures ANOVA. Where appropriate, all statistically sig-4.40, p = 0.04] and cell suspension graft treatments nificant interactions were followed up with the post hoc [F(1, 14) = 4.31, p = 0.04]. Furthermore, post hoc analy-Tukey Test for mean comparisons. For descriptive stasis of mean rotational scores indicate postgraft rotational tistics, means are reported with their corresponding scores for the pGDNF DNP treatment groups were sig-SEM.
nificantly lower than scores for saline treatment groups RESULTS
for both graft types [p = 0.02 pGDNF DNPs + chunk graft vs. saline + chunk graft (postgraft); p = 0.03 pGDNF
Experimental Design
DNPs + cell suspension graft vs. saline + cell suspen- Figure 2A illustrates the experimental timeline of sion graft (postgraft)]. these studies. Rats received unilateral 6-OHDA lesions Spontaneous forelimb activity was monitored in each of the left nigrostriatal pathway. Lesion severity was deanimal using the cylinder test. Cylinder tests scores were termined 4 weeks later using amphetamine-induced rotaobtained 1 week prior to the 6-OHDA lesion (prelesion), tional behavior and the cylinder test. One week later, 4 weeks postlesion and 1 week before sham or DNP animals received four deposits of pGDNF DNPs or treatment (pregraft), and 4-5 weeks postgraft. Figure 4 sham injections of saline into the denervated (left) striasummarizes the results of these tests. Statistical analysis tum as shown in Figure 2B . One week after the intrastrirevealed a significant Treatment × Time for these experatal injections of pGDNF DNPs or saline, either a cell iments: for tissue chunk grafts [F(1, 6) = 10.12, p < suspension or tissue chunk graft of fetal VM tissue was 0.01] and for cell suspension treatments [F(1, 8) = 6.40, placed between the injection sites of DNPs, as shown in p < 0.01]. All groups showed a significant reduction in Figure 2B . Grafts were allowed to integrate for a 6-week contralateral forepaw usage following the lesion (prepostgraft period. graft). Animals receiving tissue chunk grafts or cell sus-GDNF Protein Levels in the Striatum Transfected pensions grafts that were also pretreated with pGDNF With pGDNF DNPs DNPs showed a statistically higher percentage of right forepaw usage at the postgraft time point when com-Three naive animals received left intrastriatal injecpared to grafted animals receiving saline pretreatment. tions of pGDNF DNPs in the same sites shown in Figure  2B but did not receive grafts. One week later animals Histological Analysis of Grafts Implanted Into were euthanatized and the left and right striata were disthe Striatum Transfected With pGDNF DNPs sected for protein analysis. For GDNF protein levels, Figures 5 and 6 show typical examples of TH immuthere was a significant effect of side [t(4) = 9.57, p < nohistochemistry for cell suspension or chunk grafts 6 0.001] with GDNF levels of 0.55 ± 0.04 ng/g tissue on weeks postgrafting. In grafts containing 400,000 cells the injected side when compared to 0.07 ± 0.02 ng/g tisprior to transplantation, we normally see a low yield of sue of GDNF on the noninjected side. Previously we TH + cells 1 month following transplantation, as shown reported a short term (1-2 week) upregulation of GDNF in the left photomontage in Figure 7 for a suspension protein in the denervated striatum following a 6-OHDA graft. On the other hand, grafts placed into the striatum lesion (50); however, subsequent unpublished data from treated with pGDNF DNPS show larger grafts and more our laboratory has shown that at 4 weeks postlesion, extensive fiber outgrowth from the graft. Moreover, us-GDNF protein levels in the denervated striatum are ing a stereological cell counting technique to quantify equivalent to GDNF protein levels in the intact striatum the number of TH + cells within each graft ( Fig. 8 ), we so we do not anticipate there was any compensatory determined there was a statistically significant effect of upregulation of GDNF within the denervated striatum treatment, with 16-fold more TH + cells within chunk that was due to the lesion itself at the time the samples grafts placed into the striatum pretreated with pGDNF were taken.
DNPs (14,923 ± 4,326) than in chunk grafts placed into Effect of Brain Transfection/Graft on Behavior the sham pretreated striatum (955 ± 343) [t(6) = 3.49, p < (Rotational Behavior and Cylinder Test) 0.05]. Similarly, for cell suspension grafts we determined there was a statistically significant effect of treat-Rotational behavior was initially tested 4 weeks following a unilateral 6-OHDA lesion of the left nigrostria-ment, with sevenfold more TH + cells within cell suspen- sion grafts placed into the striatum pretreated with pension grafts implanted into striatum transfected with pGDNF DNPs. pGDNF DNPs (5,445 ± 1,272) than in suspension grafts placed into the sham pretreated striatum (727 ± 208) DISCUSSION [t(6) = 2.73, p < 0.05].
Graft volumes were estimated using the Cavalieri Here we report that plasmid DNA encoding for the neurotrophic factor GDNF can be compacted into rod-method and are reported in Table 1 . We observed an eightfold increase in graft volume for chunk grafts im-like nanoparticles ranging in size from 8 to 11 nm in diameter, injected into the denervated striatum, and ef-planted into the striatum pretreated with pGDNF DNPs and a fourfold increase in graft volume size for cell sus-fectively transfect cells in the brain so that transgene expression of GDNF attained levels that are neuro-(4-6 weeks) effects of this nonviral gene therapy technique. A previous study that used these same DNPs trophic for grafted dopamine neurons. This nonviral nucleic acid delivery technology has largely overcome var-demonstrated reporter gene expression in the striatum 8-11 weeks following the injection of DNPs (51) . We ious physiologic barriers to introducing DNA into the nuclei of nondividing cells. This technology is based on also observed overexpression of GDNF in the striatum that lasted at least 3 weeks postinjection (longest time condensation of single molecules of nucleic acids with polyethylene glycol (PEG)-substituted lysine peptides to point measured). Therefore, injecting the DNPs 1 week prior to grafting would provide at least 2 weeks of formulate nanoparticles having the minimum possible theoretical size based on the partial specific volumes of GDNF overexpression during the postgraft period. Previously we showed that osmotic minipump infusion of lysine and DNA (24) . These DNA nanoparticles are stable >3 years at 4°C, nonimmunogenic (repeat dosing in GDNF protein into the graft site during the first 2 weeks postgrafting substantially increased the survival of TH + the lungs of mice has been demonstrated), noninflammatory (55) , and very effective in the lung (18,54), eye cells in single chunk grafts (47). In terms of the survival of TH + cells, the effect of transfecting the striatum with (14) , and more recently in the brain (51) . In an intranasal cystic fibrosis clinical trial, no adverse events were at-pGDNF DNPs and overexpressing GDNF protein in the transplant site exceeded what we observed following the tributed to the DNPs and most subjects demonstrated partial to complete electrophysiologic correction of the direct infusion of GDNF protein into the transplant site, which was a three to fourfold increase in the number of CFTR chloride channel defect (19) .
This study was designed to examine the short term surviving TH + cells (49) . While it is possible that GDNF overexpression may have continued beyond the 2-week Volumetric analysis indicates graft size increased four to eightfold when the grafts were implanted in be-postgrafting period in the present study and for this reason may have contributed to the greater survival of tween the four sites injected with pGDNF DNPs. One of the grafts in the chunk graft/pGDNF DNP group was grafted TH + cells, there may be other reasons why we observed a difference between the studies. As discussed 14 times larger (2.1 mm 3 ) than the mean volume measurement for grafts in the chunk graft/sham group (0.15 earlier, grafted embryonic cells are most susceptible to necrotic and apoptotic cell death during the first week mm 3 ). Not only did we observe an increase in the survival of grafted TH + cells, we observed larger grafts in postgrafting. Neurotrophic factor intervention during this brief period may be all that is required to keep these general suggesting a trophic effect to the nondopaminergic components of the grafts as well. We were unable cells viable in the short term. We must also consider that in the present study four transfection sites surrounding to measure fiber outgrowth in this study because some of the pGDNF DNP-treated grafts were so large that the graft were used for pGDNF DNP treatment while only a single injection site was used in the earlier GDNF they occupied most of the medial-to-lateral extent of the striatum (Fig. 5a ). Future studies will require an adjust-protein infusion study, which may have resulted in smaller brain volumes having neurotrophic support. In sum-ment of the DNP dosing in order to correct for oversized grafts. mary, we speculate that GDNF protein levels as well as volume of brain distribution may account for the supe-Functionally, grafts placed into the denervated striatum that was previously transfected with pGDNF DNPs rior results seen in this DNP gene transfer study compared to the prior GDNF protein infusion protocol.
provided better compensatory effects in terms of im-proved scores for forelimb activity. While both cell sus-The size of the DNPs used in this study may be an important factor for the successful transfection of brain. pension and chunk grafts treated with saline showed a trend for improved cylinder test scores, their postgraft Several studies using DNPs with diameters in the range of 80-100 nm reported only short-term transgene ex-scores were not statistically greater than their pregraft scores (p = 0.20 for chunk grafts; p = 0.61 for cell sus-pression and limited success. For instance, Leone et al.
(21) used a nonviral, lipid entrapped, polycation con-pension grafts). Rotational behavior indicates all grafts in all treatment groups were functional in terms of re-densed delivery system (LPD) to induce transgene expression in the brains of rodents, primates, and humans; ducing amphetamine-induced rotational behavior, and prior transfection of the striatum with pGDNF DNPs re-these nanoparticles had an average particle size of 80-100 nm in diameter. However, this nonviral system sulted in an even higher reversal of rotational behavior than grafts alone. It is interesting that we observed over demonstrated only limited success. Polyethylenimine/ DNA (PEI/DNA) complexes have been used as a nonvi-a 2.5-fold increase in the number of TH + cells in the chunk graft/pGDNF DNP group when compared to the ral gene technique to delivery DNA to mammalian cells (29). Oh et al. injected PEI/DNA nanoparticles (ϳ100 cell suspension graft/pGDNF DNP group and similar rotational and cylinder scores for both groups. In some nm) into dog brain with minimal toxicity (30); however, in this same study it was also reported that intracerebral cases it is possible that the large size of grafts in the chunk graft/pGDNF DNP group may have displaced a injection of plasmids encoding for reporter genes as naked plasmids or PEI/DNA complexes elicited nearly large amount of striatal tissue and actually interfered with the ability of the graft to successfully reinnervate equivalent levels of transgene activity at 3 days, suggesting no real benefit for the PEI/DNA complexes. Effi-the host striatum and, as a consequence, limited the degree of functional recovery. ciency problems in initial nanoparticle gene delivery studies were most likely due to the fact that these com-vectors because of their noninflammatory and nonimmunogenic properties (13, 55) ; immunogenicity is an inher-plexes were still too large to diffuse efficiently in the extracellular brain matrix (46) or cross the 25-nm nu-ent problem with many viral vectors (45) , especially if viral vectors need to be redosed (25) . In fact, compacted clear membrane pore, or may have been degraded in the cell cytoplasm. More recently, we and others have dem-DNA can be repetitively dosed to murine airways without any decrement in transgene expression (Copernicus, onstrated successful transfection of brain cells using smaller nanoparticles. For instance, Bharali et al. reported unpublished data), suggesting that chronic administration is feasible. We observed only a minimal amount successful transgene expression of reporter genes and neurotrophic factor in brain following direct intracere-of immune activity within the injection site based upon macrophage (ED-1) and cytotoxic T cell (OX-8) immu-bral injection of encapsulated DNA plasmids within ϳ30 nm silica nanoparticles (7) . We reported successful long-nohistochemical stains; these minor changes were found in both DNP and saline groups and therefore appear to term transgene expression in brain using PEG-substituted lysine peptide DNA rod-like nanoparticles (ϳ8-12 be due to the injection procedure itself and not the DNPs (51) . Because a major component of the nanoparticles is nm in diameter) as a vehicle for gene delivery (51) . Of note, polymeric small nanoparticles (<25 nm) but not lysine polymers, the issue of poly-lysine toxicity needs to be addressed. One of the toxic effects of synthetic larger nanoparticles (>42 nm) appear to enter cells and traffic through the cytoplasm of cells using a nondegra-DNA complexes, such as poly-lysine or polyethyleneimine (PEI), is the activation of complement; the comple-dative pathway, which underscores the importance of using small size particles to deliver plasmid DNA to the ment system, or the nonspecific defense system, protects vertebrate species from invasion by foreign organisms. nucleus (20) .
Compacted DNA is an attractive alternative to viral Plank et al. demonstrated the activation of complement by poly-lysine is a function of the chain length of poly-particles are charge neutral or slightly negative. Moreover, conjugation of PEG and/or transferrin to unbound lysine (33) . In this study it was shown unbound longchain (>50 mer) poly-lysine activated complement but poly-lysine or poly-lysine/DNA complexes had a further protective effect against the activation of complement that activation was substantially decreased for unbound short-chain (<50 mer) poly-lysine; this is one reason (33) . These data suggest there is a minimal immunogenic response to the injection of poly-lysine/DNA na-why we chose to use a small-chain 30-mer lysine polymer in our nanoparticle formulation. In a side-by-side noparticles.
In summary, we demonstrated a nonviral gene ther-comparison between poly-lysine and PEI, it was shown that unbound PEI was a much stronger activator of com-apy technique can be used in combination with neural grafts to enhance both the survival of grafted embryonic plement than unbound long-chain poly-lysine. Secondly, it was shown that the toxicity of poly-lysine is reduced dopamine neurons and functional recovery in an animal model of PD. DNA plasmids encoding for GDNF and when it is bound to other moieties, including DNA: poly-lysine/DNA complexes with neutral or slightly nega-compacted into nanoparticles were used to transfect the denervated striatum prior to graft implantation. Subse-tive charge did not activate complement at all (33, 34) . This is significant because our compacted DNA nano-quently, grafts implanted into the denervated/transfected Figure 7 . Photomontage of serial brain sections immunostained for tyrosine hydroxylase (TH) and showing the denervated/grafted striatum in an animal that was pretreated with compacted pGDNF DNPS (right) or saline (left) 1 week prior to suspension graft surgery. Chronology of treatments: animals received a complete lesion of the nigrostriatal pathway, 6 weeks later either compacted pGDNF nanoparticles or saline was injected into the denervated striatum and then 1 week later a fetal VM cell suspension grafts was implanted into the denervated/transfected striatum. Grafts developed in the striatum for 6 weeks before animals were euthanatized and brains removed for histological examination. Brain sections are 40 µm thick and every third section through the graft site is shown for each animal; sections are arranged so that the rostral striatum is near the top and caudal striatum is at bottom. Graft cells were taken from the ventral mesencephalon of E13-E14 fetuses (200,000 cells/µl; 2.0 µl). Scale bar: 1 mm. covery was also improved using this combined nonviral gene therapy/grafting technique. This study demonstrates eases. Brundin 
